Lobbying Expenditures in the US Health Care Sector, 2000-2020
Level 4 - case-series / case-control
Cross-sectional analysis of public disclosure data (by design analogy, non-clinical)
OpenAlex W4307468266 · doi:10.1001/jamahealthforum.2022.3801
What was done
This cross-sectional study evaluated trends in lobbying expenditures across US health care industries from 2000 to 2020 using publicly available, nonpartisan data.
What was found
The abstract provides no quantitative data, directional trends, or specific findings.
Why it matters
Characterizing lobbying expenditures identifies how financial resources are deployed across health care sectors to influence policy.
Limits
The abstract contains no numeric results, sample sizes, or descriptive details. The design is purely observational and dependent on the completeness of public disclosure filings.
Cited by
- supports Annual lobbying spending by the pharmaceutical industry in the United States far exceeds that of any other industry, including defense and technology.